The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease.
- Resource Type
- Academic Journal
- Authors
- Jones EM; Bristol Centre for Antimicrobial Research and Evaluation, Southmead Health Services NHS Trust and the University of Bristol, Southmead Hospital, Westbury-on-Trym, UK. lesassays@ukneqasaa.win-uk.net; McMullin CM; Hedges AJ; Lovering AM; White LO; Reeves DS; MacGowan AP
- Source
- Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print Cited Medium: Print ISSN: 0305-7453 (Print) Linking ISSN: 03057453 NLM ISO Abbreviation: J Antimicrob Chemother Subsets: MEDLINE
- Subject
- Language
- English
- ISSN
- 0305-7453
Serum concentrations of ciprofloxacin were reviewed in 22 patients given ciprofloxacin 400 mg intravenously 12 hourly for severe infection. No dosage modifications were made in patients with renal impairment. Patients who had either bowel or liver pathology in addition to renal failure had significantly higher serum concentrations than all other patients. Dosage reduction of ciprofloxacin in patients with severe sepsis and impaired renal function is not required unless they have co-existent intra-abdominal disease.